Workflow
石药集团：SYH2070注射液在美国获临床试验批准
CSPC PHARMACSPC PHARMA(HK:01093) Zheng Quan Shi Bao Wang·2025-10-09 10:16

Core Viewpoint - The company has received FDA approval for its self-developed chemical Class 1 new drug SYH2070 injection, a double-stranded small interfering RNA (siRNA) drug, allowing it to conduct clinical trials in the United States [1] Group 1 - The drug SYH2070 injection has also been approved by the National Medical Products Administration (NMPA) of China to conduct clinical trials starting from September 2025 [1]